AE	Adverse event
CI	Confidence interval
eGFR	Estimated glomerular filtration rate
HR	Hazard ratio
ICI	Immune checkpoint inhibitor
LEN	Lenvatinib
MKI	Multi-target tyrosine kinase inhibitor
NCCN	National Comprehensive Cancer Network
NE	Not estimable
NLR	Neutrophil-to-lymphocyte ratio
ORR	Objective response rate
OS	Overall survival
PBO	Placebo
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
PS	Performance status
RAI	Radioactive iodine
RAIR-DTC	Radioiodine-refractory differentiated thyroid cancer
RECIST v1.1	Response evaluation criteria in solid tumors version 1.1
TEAE	Treatment-emergent adverse event
TKI	Tyrosine kinase inhibitor
VEGF	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor